JM, van Rijen HV. Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am J Physiol Heart Circ Physiol 299: H310 -H321, 2010. First published April 30, 2010; doi:10.1152/ajpheart.01137.2009.-Myocardial fibrosis increases arrhythmia vulnerability of the diseased heart. The reninangiotensin-aldosterone system (RAAS) governs myocardial collagen synthesis. We hypothesized that reducing cardiac fibrosis by chronic RAAS inhibition would result in reduced arrhythmia vulnerability of the senescent mouse heart. Wild-type mice (52 wk old) were treated for 36 wk: 1) untreated control (C); 2) eplerenone (E); 3) losartan (L); and 4) cotreatment with eplerenone and losartan (EL). Ventricular epicardial activation mapping was performed on Langendorff-perfused hearts. Arrhythmia inducibility was tested by one to three premature stimuli and burst pacing. Longitudinal and transverse conduction velocity and dispersion of conduction were determined during pacing at a basic cycle length of 150 ms. Sirius red staining (collagen) was performed. As a result, in the RV of mice in the E, L, and EL groups, transverse conduction velocity was significantly increased and anisotropic ratio was significantly decreased compared with those values of mice in the C group. Anisotropic reentrant arrhythmias were induced in 52% of untreated mice and significantly reduced to 22%, 26%, and 16% in the E, L, and EL groups, respectively. Interstitial fibrosis was significantly decreased in both the RV and LV of all treated groups. Scattered patches of replacement fibrosis were found in 90% of untreated hearts, which were significantly reduced in the E, L, and EL groups. A strong correlation between the abundance of patchy fibrosis and arrhythmia inducibility was found. In conclusion, chronic RAAS inhibition limited aging-related interstitial fibrosis. The lower arrhythmogeneity of treated mice was directly correlated to the reduced amount of patchy fibrosis.
portant factors in the formation of the arrhythmogenic substrate. Previously, we have characterized a mouse model of age-induced arrhythmias, which were attributable to increased interstitial and replacement fibrosis (22) .
Cardiac collagen is produced by fibroblasts, secreting procollagen into the interstitial space (17) . This process is influenced by various substances, two of which are angiotensin II and aldosteron (9) . Various reports indicated that the inhibition of either one of these pathways results in a lesser amount of cardiac fibrosis, either in the setting of atrial fibrillation (14) , heart failure (2), or myocardial infarction (8) .
Inserra and coworkers (10) treated mice for 24 mo with the angiotensin-converting enzyme (ACE) inhibitor enalapril, which resulted in a 10-fold reduction of ventricular interstitial fibrosis, compared with that in untreated controls. More recently, Qu and coworkers (21) treated pressure overloaded mice with the mineralcorticoid antagonist spironolactone, resulting in a prevention of gap junction remodeling, reduced fibrosis, and normalization of impulse conduction (21) . Clearly, renin-angiotensin-aldosterone system (RAAS) inhibition results in a strong inhibition of cardiac fibrosis. The effect on arrhythmogeneity is, however, currently unclear.
In this study, we have treated 12-mo-old mice for 10 mo with either eplerenone or losartan, or a combination of both, as an instrument to attenuate fibrosis formation. We hypothesized that attenuating age-related cardiac fibrosis by chronic RAAS inhibition would reduce the susceptibility of aged hearts to ventricular arrhythmias.
This study shows that chronic RAAS inhibition resulted in the reduction of both interstitial and patchy fibrosis in the senescent heart. Interestingly, the significant reduction of arrhythmia vulnerability was directly correlated to the reduction of patchy fibrosis.
MATERIALS AND METHODS

Animals
One hundred twenty-four female wild-type C57BL/6 mice (52 wk old) were purchased from Charles River and Harlan. Mice were divided into four groups (n ϭ 31 per group), depending on treatment: group 1, untreated control (C); group 2, eplerenone [E; 200 mg·kg Ϫ1 · day Ϫ1 (20) ; received through chow]; group 3, losartan [L; 10 -15 mg · kg Ϫ1 · day Ϫ1 (16) ; received via drinking water]; and group 4, cotreatment of eplerenone and losartan (EL; identical dosage as groups 2 and 3). Treatment was given from 54 to 86 wk of age. Food and water were given ad libitum. Medication intake was monitored weekly as was control of body weight and food and water consumption. Not all animals survived up to the age of 86 wk, but this was not different between the four groups (C, 23 
Noninvasive Blood Pressure Measurements
Noninvasive blood pressure (NIBP) measurements, ECG, and Doppler echocardiography recordings were performed before drug administration was started (age, 54.5 Ϯ 0.17 wk) and before Langendorff perfusion experiments (age, 86.5 Ϯ 0.2 wk). Drug administration was ceased at five times t 1/2 of the drug (L, t1/2 ϭ 6 -9 h; and E, t1/2 ϭ 2 to 3 h) to eliminate any influence during electrophysiological measurements.
Mice were placed under marginal isoflurane anesthesia allowing for measurements (0.2-0.4% isoflurane in oxygen). A pressure cuff was adjusted at the base of the tail. Doppler echocardiography was used to detect the arterial signal. With the use of a sphygmomanometer, the cuff was gradually inflated 20 mmHg above the point of which no arterial signal was detected. Subsequently, the cuff was gradually deflated. The moment the arterial signal was again detected was determined as systolic blood pressure (SBP; in mmHg). The cuff was further deflated until the maximal signal is measured again, which is defined as the diastolic blood pressure (DBP; in mmHg). This procedure was repeated at least three times. The average of the measurements was considered as SBP or DBP.
Doppler Echocardiography
Transthoracic Doppler echocardiography was performed as previously described (23) on isoflurane-anesthetized mice. A digital cardiac ultrasound platform (SONOS 5500, D1 software package, Philips Medical Systems) with a 15-MHz linear scanner (M-and B-mode) and a 12-MHz short focal length-phased array transducer (Doppler) were used. The end-diastolic and end-systolic dimensions of the LV cavity and the thickness of the anterior and posterior walls were assessed. Fractional shortening (in %) and ejection fraction (in %) as a measure of LV systolic function were calculated from M-and B-mode data, and Doppler recordings were performed as previously described (23) . Cardiac output was calculated from the B-mode and Doppler data.
ECG Recording
A three-lead ECG was recorded simultaneously with the Dopplerechocardiography measurements using Ag/AgCl electrode pellets and a custom-built ECG-amplifier with a 1-kHz low-pass filter setting (24) and was analyzed off-line using Chart 5 Pro (ADInstruments).
Epicardial Mapping
After cervical dislocation, the heart was excorporated, prepared, and connected to a Langendorff perfusion setup as previously described (26) . The perfusion medium composition was specified elsewhere (28) . Electrical recordings of the right and left ventricle (RV and LV, respectively) were made with a 208-point electrode (16 ϫ 13 grid; and spacing, 500 m). The ventricles were stimulated from the center of the grid at a basic cycle length of 150 ms. Recordings were made in unipolar mode with regard to a reference electrode connected to the support of the heart. Electrograms were acquired using a 256-channel data acquisition system (Biosemi, Amsterdam, The Netherlands). Signals were low-pass filtered [1 kHz (6 dB)] and digitized with 24-bit resolution at a bit step of 2 V and a sampling frequency of 2 kHz. The input noise of the system was 4 V (peak-peak).
The effective refractory period (ERP), the longest coupling interval of the premature stimulus that failed to activate the entire heart, was determined for each ventricle separately. Every sixteenth stimulus was followed by one premature stimulus. At the start of 140 ms, the coupling interval of the premature stimulus was reduced in steps of 10 ms until ERP (24) .
The susceptibility to arrhythmias was tested by applying 16 basic stimuli (basic cycle length, 150 ms) followed by 3 premature stimuli with an interval of ERP ϩ 5 ms and by burst pacing if premature stimulation failed to induce arrhythmias. Burst pacing was done for 2 s at intervals starting at 20 ms above ERP down into steps of 5 ms till ventricular tachycardia (VT)/ventricular fibrillation was induced or one-to-one capture was lost.
The moment of maximal negative first derivative of the unipolar electrogram voltage (dV/dt) in the unipolar electrograms was selected as the time of local activation and determined with custom-written software based on MatLab (The Mathworks) (19) . The activation times were used to construct activation maps. Conduction velocity parallel (longitudinal; CV L) and perpendicular (transverse; CVT) to the fiber orientation were determined from the paced activation maps. The activation times of at least three consecutive electrode terminals along lines perpendicular to the intersecting isochronal lines (1 ms) were used to estimate the conduction velocities. The dispersion of conduction was assessed for the LV and RV using the method described by Lammers et al. (15) .
Statistics
Statistical analysis was performed using a two-way ANOVAelectrophysiological parameters, tissue characteristics [interstitial fibrosis and connexin 43 (Cx43) protein expression], and organ weight-or two-way repeated-measurement ANOVA (NIBP, ECG, and echocardiography data). A post hoc analysis was performed using either Dunnett's test (two-way ANOVA) or Holm-Sidak's test (twoway repeated-measurement ANOVA). All values are means Ϯ SE. Nonparametric data were statistically analyzed using 2 test. Data were analyzed by using either SPSS 13.0 or SigmaStat 3.1.
Immunohistochemistry and Histology
(Immuno)histology was carried out on 42 hearts: three young hearts (12 wk old, serving as control for C), n ϭ 11 C, n ϭ 10 E, n ϭ 9 L, and n ϭ 9 EL hearts. Sections (10 m) from different levels (interspaced 150 m) were immunolabeled to assess the expression and distribution of Cx43 reported previously (26) .
To evaluate the amount of fibrosis, sections serial to the ones used for antibody labeling were stained with Picro Sirius red. For each ventricle, a minimum of four randomly chosen areas were analyzed by microscopy at ϫ200 magnification. Using Adobe Photoshop 7.0 (Adobe Systems) software, the number of red (collagen) and yellow (tissue) pixels were counted and the percentage of fibrosis [red pixels/(red ϩ yellow pixels)] was determined.
To determine the presence of replacement fibrosis, four gradations of replacement fibrosis prevalence was determined: none (0), scant (ϩ), moderate (ϩϩ), and severe (ϩϩϩ).
Operators were blinded for treatment.
Western Blot Analysis
Total cellular protein was isolated from the LV and RV free wall of 36 hearts (6 hearts from each group; 3 with and 3 without inducible arrhythmias) (26) . An interventricular comparison was performed among the C, E, L, and EL groups.
To quantify Cx43 protein expression, the differences in specific protein concentration were determined as follows. Processed films and Ponceau red staining (grayscale scanned) were imported into ImageQuant software to measure separate protein band intensity. Cx43 protein band signal is controlled to exclude saturation. Unequal protein loading is corrected against total applied protein; the ratio Cx43/Ponceau red signal intensity represents the actual Cx43 protein concentration of the different lanes. 
Antibodies
The following antibodies were used: mouse monoclonal antibodies raised against dystrophin (1:1; Novocastra), mouse monoclonal antibodies raised against Cx43 (1:150; Transduction Laboratories), rabbit polyclonal antibodies raised against Cx43 (1:250; Zymed), and 4=,6-diamidino-2-phenylindole (DAPI) nucleic acid stain (1:100; Invitrogen-Molecular Probes). Secondary antibodies (Texas red and FITCconjugated whole IgG) were purchased from Jackson.
RESULTS
Functional Measurements
NIBP measurements. At 54 wk of age (measurement 1), DBP and SBP were similar between the untreated and treated groups. At 86 wk of age (measurement 2), DBP was decreased but similar between the untreated and treated groups. However, SBP was significantly lower in all of the treated groups compared with the untreated control. Supplemental Table S1 , part A, summarized the NIBP measurements performed (note: supplemental material may be found posted with the online version of this article).
Surface ECG. No difference was found in the R-R interval between the untreated and treated groups of both time points 1 and 2. The P-R interval was prolonged with age but was not different between the untreated and treated groups. The P wave and QRS duration of the treated groups were comparable with the controls, both at time points 1 and 2. For detailed electrocardiographic characteristics, see supplemental Table S1 , part B. Values are means Ϯ SE; n, number of hearts or number of hearts affected out of total hearts (indicated in parentheses). RV, right ventricle; LV, left ventricle; CVL and CVT, longitudinal and transverse conduction velocity, respectively; ERP, effective refractory period; VT, ventricular tachycardia. *P Ͻ.05, differences between untreated and treated groups. † 2 analysis for nonparametric test. ‡Statistically significant differences between groups (2-way ANOVA).
Echocardiographic characteristics. Supplemental Table S1 , part C, summarizes the Doppler echocardiographic measurements. No echocardiographic differences were measured between the untreated and treated groups, neither during measurement 1 nor measurement 2. In all of the groups, agingrelated physiological hypertrophy with slight dilatation of the LV occurred. As indicated by the preserved fractional shortening and ejection fraction, systolic function was maintained with age; cardiac output slightly increased (see supplemental  Table S1 , part C). No LV wall motion abnormalities were measured, excluding myocardial infarctions. Two mice with valve abnormalities were excluded from the study. Fig. 1 . Myocardial fiber orientation at the epicardium of the RV and LV is indicated by the black double-headed arrows in the heart pictograms. Red denotes the earliest activation time, and blue, the latest. In the LV, both CV L and CV T remained unaltered between the untreated and treated animals ( Table 1 , Electrophysiological characteristics). In the RV, CV L was also unaltered in the treated groups. However, in the RV, CV T was significantly faster in the E, L, and EL hearts compared with the RV of the untreated hearts. Isochronal lines revealing transverse conduction are less crowded in the treated than the untreated RVs (Fig. 1) . As a result, the RV anisotropic ratio (CV L /CV T ) of E, L, and EL hearts decreased significantly compared with that in C hearts. Anisotropy was similar in the LVs of the four groups (Table 1 , Electrophysiological characteristics).
Electrophysiological Characteristics
The dispersion of conduction was unaltered in both the RV and LV of the treated groups, compared with the untreated RV and LV, respectively. ERP and excitation wavelength for transverse propagation, (CV T ϫ ERP), did not differ between the treated and untreated groups, both in the RV and LV.
Arrhythmogeneity. When compared with those in our previous study (22) , all arrhythmias were (non)sustained monomorphic VTs (MVTs), which were predominantly initiated and sustained in the RV and were all based on anisotropic reentry. Overall arrhythmogeneity was reduced by RAAS inhibition, albeit not significantly ( 2 ϭ 0.14), from 52.2% ( mice, respectively; P ϭ 0.94) and ERP (44.9 Ϯ 2.6 vs. 38.8 Ϯ 4.1 ms in VT ϩ and VT Ϫ mice, respectively; P ϭ 0.212). The excitation wavelength was 1.47 Ϯ 0.08 vs. 1.28 Ϯ 0.1 cm in VT ϩ and VT Ϫ mice, respectively (P ϭ 0.161). Figure 2 shows typical examples of an MVT induced in the RV of an eplerenone ( Fig. 2A)-or losartan (Fig. 2B) -treated heart. The monomorphic-sustained VT induced in the eplerenone-treated heart was induced by burst pacing. The MVT in the losartan-treated heart was induced by three premature stimuli. In Fig. 2, A and B , the activation maps are from two consecutive complexes showing that the impulse revolves around a zone of block, evidenced by the crowding of the isochronal lines. Propagation is clockwise in the E-sustained VT and counterclockwise in the L-nonsustained VT. In both examples, conduction is fast parallel to myocardial fiber orientation (top down) and slow perpendicular to fiber orientation, indicative of anisotropic reentry tachycardia.
Tissue Characteristics
Organ weight. No significant differences were measured between body, heart, lung, or liver weights of the untreated and treated groups (for details, see supplemental Table S2 ).
Expression and distribution of Cx43 protein. Senescent (86 wk old) hearts show a reduction and redistribution in the amount of Cx43 compared with adult (12 wk old) hearts in both the RV and LV (Fig. 3) . Cx43 expression is polarized to the intercalated disks in senescent mice.
When compared with the untreated senescent control group, the treated groups overall show an equal amount of Cx43 expression. Cx43 Western blot analysis did not reveal any significant differences between the untreated and treated groups, both of the RV and LV (Table 1, Cx43 protein expression). No differences in Cx43 phosphorylation were observed between the different groups. However, treatment resulted in the attenuation of Cx43 polarization, typical for untreated senescent mice (Fig. 4) .
Interstitial fibrosis. Sirius red staining of adult (12 wk) RV and LV shows slender and comparable interstitial collagen that is homogeneously present throughout the ventricles (Fig. 3,  bottom, left) . However, untreated senescent (86 wk) RV and LV showed an increased density of interstitial fibrosis, though homogeneously distributed (Fig. 3, bottom, right) . Interstitial fibrosis levels of untreated senescent mice were 7.64 Ϯ 0.15% in the RV and 7.27 Ϯ 0.15% in the LV of the untreated groups (Table 1, Fibrosis) . In both the RV and LV of the treated groups, interstitial fibrosis was clearly reduced (Fig. 5) . In both ventricles, interstitial fibrosis was significantly reduced by 45%, 48%, and 41% in the RVs of the E, L, and EL groups, respectively, and 41%, 37%, and 45% in the LVs of the E, L, and EL groups, respectively, compared with that in the C group (Table 1, Fibrosis). Cotreatment with eplerenone and losartan was not more effective than single treatment.
Replacement fibrosis and arrhythmogeneity. In contrast to the homogeneously distributed interstitial fibrosis, patches of severe fibrosis were heterogeneously distributed throughout the RV and LV of the four study groups. Patchy fibrotic areas demonstrated a reduction and redistribution of Cx43 gap junctions and practically absent cell nuclei (DAPI), indicating replacement fibrosis (data not shown).
Though the prevalence of replacement fibrosis varied between the four groups, localization was restricted to the endo-and midmyocardial layers of the LV (Fig. 6, A and B) and located throughout the entire RV free wall (Fig. 6, C  and D) .
Severity of patchy fibrosis was categorized in four levels: no patchy fibrosis (Fig. 7A), scant (Fig. 7B) 7C), and severe (Fig. 7D ) patchy fibrosis. Arrows indicate areas of replacement fibrosis. Table 1 (Fibrosis) specifies the prevalence and severity of patchy fibrosis for all four groups. Out of 11 examined untreated hearts, 90.91% had some form of replacement fibrosis. The prevalence of replacement fibrosis was significantly reduced (P ϭ 0.005) in the treated groups to 50% in the eplerenone, 55.56% in the losartan, and 44.44% in the cotreatment groups (Fig. 7E,  Table 1, Fibrosis) .
A strong significant correlation (P ϭ 0.005) was found between the severity of replacement fibrosis and arrhythmogeneity, regardless of the treatment (Fig. 7F) ; no arrhythmias were induced in hearts where replacement fibrosis was absent (n ϭ 0 of 15). Arrhythmias were induced in 18.2% (n ϭ 2 of 11) of hearts with a scant amount of replacement fibrosis, 44.4% (n ϭ 4 of 9) of hearts with a moderate amount, and as much as 75% (n ϭ 3 of 4) of hearts with severe replacement fibrosis. 
DISCUSSION
The key finding of this study is that chronic RAAS inhibition leads to reduced interstitial and patchy fibrosis and reduced vulnerability to arrhythmias in aged mice. The lower arrhythmogeneity was directly correlated to the reduction of patchy fibrosis.
Interstitial Fibrosis and Cell-to-Cell Coupling
Chronic RAAS inhibition resulted in 1) a reduction of interstitial fibrosis and 2) an attenuation of polarization of Cx43 to intercalated disks. Cx43 protein levels were not changed.
A reduction of interstitial fibrosis development in aging mice by chronic administration of ACE-inhibitors was previously reported (10) . In failing hearts of cardiomyopathic hamsters, a 3-mo eplerenone administration reduced interstitial fibrosis (6) . Similarly, a 4-wk treatment of mice with pressure overloaded hearts with spironolactone resulted in reduced fibrosis (21) . The chronic effects of either angiotensin receptor antagonists or aldosterone inhibitors have not been extensively studied in animal models, although clinical studies show an improved outcome (reduced collagen) of patients treated with either losartan (2) or eplerenone (8, 14) . In our study, the coadministration of both drugs did not have an additive effect and did not result in lower amounts of interstitial fibrosis in the EL group compared with the single-treated animals.
The effect of the RAAS system on Cx43 protein expression and distribution has been previously investigated (11) , demonstrating that ACE overexpression results in a dysregulation (reduction and redistribution) of the protein. Aging is accompanied by a reduction of Cx43 expression as is described by Boengler et al. (4) . In our study, treatment did not result in an increased Cx43 protein quantity, but the effect of aging on the polarization of Cx43 from the lateral sarcolemma to the intercalated disc, which was previously described in rabbits (7), was attenuated in the treated hearts. The attenuation of Cx43 polarization to the intercalated discs might be explained by the decreased amount of interstitial fibrosis between the myocytes, allowing for the presence of Cx43 in the lateral sarcolemma of the cells. The higher levels of Cx43 at the lateral borders of the myocytes may contribute to the increased CV T in the treated groups.
Improvement of Conduction Velocity and Anisotropy in Treated Hearts
Aging-induced increased interstitial fibrosis has been previously reported (22, 25) and was correlated to conduction slowing perpendicular to myocardial fiber orientation, increased anisotropic ratio, and arrhythmogeneity. When compared with that in this study, CV T of aged animals was reduced in RV but not in LV. The amount of interstitial fibrosis was comparably increased in both aged RV and LV.
In this study, chronic RAAS inhibition resulted in a significantly reduced interstitial fibrosis quantity, both of the RV and the LV. Interestingly, only the RV impulse conduction is positively affected by this reduction, indicating the specific vulnerability of the RV for changes in tissue characteristics.
Replacement Fibrosis Expression and RV Arrhythmia Susceptibility to Arrhythmias
A key finding in this study is the presence of heterogeneously distributed patchy fibrosis. It is unclear whether the areas of patchy replacement fibrosis are caused by necrosis or apoptosis. Nadal-Ginard et al. (18) discussed these possibilities of cell death, indicating that the distinction between the two mechanisms has different consequences on cardiac remodeling. On myocyte necrosis results in scar formation, apoptosis results in the removing of the apoptotic bodies by neighboring cells with no apparent changes in the morphology of the tissue (18) . This might indicate that the areas of replacement fibrosis found in the aged myocardium are based on necrosis, possibly caused by microinfarctions. Both SBP and DBP were reduced in all three treatment groups, with the greatest blood pressure reduction in the EL group. Therefore, the incidence of patchy fibrosis cannot be explained by increased afterload. This is strengthened by the observation that no correlation was found between the severity of replacement fibrosis and DBP/SBP. Weber (27) discussed the effect of increased afterload (hypertension) with and without increased circulating angiotensin II and aldosterone. Animal models with sole isolated hyperten- sion result in reactive fibrosis that is restricted to the LV. However, models with increased circulating angiotensin II and aldosterone result in hypertension and an overall effect on the atria and ventricles. This strongly suggests that the reduction in blood pressure and the reduced incidence of patchy fibrosis are both caused by the treatment with no causal link between blood pressure and patchy fibrosis.
Patchy replacement fibrosis is present in 90% of the hearts of the untreated group and correlates with increased susceptibility to reentrant arrhythmias; in 52% of the hearts, arrhythmia were induced. The uneven vulnerability of the RV (52%) and LV (9%) to arrhythmias can be explained by the restriction of the patchy fibrosis to the mid-and endocardial layers of the LV myocardium and a widespread presence throughout the entire RV free wall. These areas may form an anatomical obstacle, causing an area of conduction block, which alongside the slower conduction create the setting for initiation and maintenance of reentrant arrhythmias. Chronic RAAS inhibition resulted in a significant reduction of the incidence of replacement fibrosis. Contrary to the reduction in interstitial fibrosis, replacement fibrosis was significantly lower after cotreatment with both eplerenone and losartan. The reduction in replacement fibrosis incidence resulted in a reduced susceptibility of the treated hearts to RV reentrant arrhythmias. The effect was largest in the EL group where patchy fibrosis occurred in 44% of the hearts and arrhythmogeneity was reduced to 16%. As mentioned previously, spots of patchy fibrosis may act as anatomical substrates favoring arrhythmias. This explanation is supported by Fig. 7F . The abundance of replacement fibrosis is strongly correlated with the susceptibility to arrhythmias. Hearts without or with low levels of patchy fibrosis are arrhythmia resistant. In contrast, hearts with high levels are susceptible to arrhythmias. The fact that patchy fibrosis, rather than interstitial fibrosis, is a key factor for conduction abnormalities and tachyarrhythmias was recently confirmed in a dog model of atrial fibrillation by Burstein and coworkers (5) .
Study Limitations
Treatment with RAAS inhibitors limited aging-related interstitial and patchy fibrosis that strongly correlated with decreased susceptibility to reentrant arrhythmias. Yet we cannot rule out the possibility that other uninvestigated treatment effects might play a role in the decreased arrhythmogeneity. Furthermore, the electrophysiological investigations have been performed in denervated hearts with programmed stimulation. It is possible that differences in the treatment regimens would be apparent in the presence of innervation. Treatment did not alter the sudden death risk, so the inducibility findings may or may not have significant clinical implications.
Conclusion
The aging myocardium demonstrates a spectrum of tissue alterations, two of which are the increased interstitial fibrosis and the reduced and redistributed Cx43. These alterations result in conduction slowing perpendicular to fiber orientation. The presence of patchy replacement fibrosis throughout the entire RV free wall subjects the RV to increased arrhythmia susceptibility. Chronic RAAS inhibition results in homogeneously decreased interstitial fibrosis and the attenuation of Cx43 polarization to the intercalated disc. Especially, the decreased prevalence of the heterogeneously distributed areas of patchy fibrosis correlated to a significant reduction of the susceptibility of the treated aged heart to reentrant arrhythmias.
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